MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue ...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -5.4x | ||
| Revenue | 20.222 M | ||
| Net Income to Company | -30.224 M |
| MDWD | Peers | Sector | |
|---|---|---|---|
Market Cap | 161.8 M | 188.6 M | 60.511 M |
Price % of 52 Week High | 62.4% | 45.8% | 59.9% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -13.6% | -10.1% | -0.7% |
1 Year Price Total Return | -0.9% | -12.0% | -14.1% |
Beta (5 Year) | 0.50 | 0.94 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 26 | 19 | 20 | 5.34 | 5.84 |
| Operating Income | (7.66) | (16) | (19) | (4.11) | (6.10) |
| Net Profit | (20) | (6.72) | (30) | (1.74) | (3.91) |
| Diluted EPS | -3.93 | -0.75 | -3.03 | -0.19 | -0.36 |
| EBITDA | (6.39) | (15) | (19) | (3.92) | (5.90) |
| Balance Sheet | |||||
| Cash & ST Invest. | 34 | 42 | 43 | 42 | 43 |
| Current Assets | 46 | 50 | 52 | 50 | 52 |
| Total Assets | 50 | 66 | 73 | 66 | 73 |
| Current Liabilities | 12 | 18 | 27 | 18 | 27 |
| Total Liabilities | 39 | 35 | 42 | 35 | 42 |
| Total Equity | 11 | 32 | 31 | 32 | 31 |
| Total Debt | 1.38 | 6.71 | 6.93 | 6.71 | 6.93 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (12) | (10) | (14) | (2.62) | (1.64) |
| Cash From Investing | (0.48) | (34) | (8.40) | 5.03 | 4.83 |
| Cash From Financing | 36 | 23 | 19 | (0.20) | (0.51) |
| Free Cash Flow | (12) | (17) | (20) | (4.82) | (2.44) |